Global In Vivo Contract Research Organization (CRO) Market – Industry Trends and Forecast to 2029

Market Analysis and Size

Contract Research Organization (CRO) services enable sponsors/manufacturers to concentrate entirely on production capacity and the enhancement of their in-house processes. Furthermore, various services ranging from drug discovery to post-marketing surveillance have made it easier for small and mid-sized biotechnological and pharmaceutical enterprises to outsource what they believe is beyond their core expertise.

Data Bridge Market Research analyses that the in vivo contract research organization (CRO) market which was USD 3.94 billion in 2021, would rocket up to USD 7.46 billion by 2029, and is expected to undergo a CAGR of 8.30% during the forecast period. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

In-vivo contract research organizations are contract research organization (CRO) that conduct biopharmaceutical research in vivo (IV-CROs). In-vivo cro are becoming more widespread as biologics overtake small molecule drugs in popularity. CROs are focused more on biosimilar development due to the high degree of competition in the development of mABs. The pipeline's focus is shifting away from traditional mABs and toward bispecifics or biosimilars. As demand for clinical scale manufacturing of active pharmaceutical components develops, integrated contract research, development, and manufacturing organizations (CDMOs) are increasing their revenue footprint across all fields.

Report Scope and Market Segmentation

In Vivo Contract Research Organization (CRO) Market Dynamics

Drivers

• Increase the number of research and development (R&D) activities

Many molecules are about to expire due to a patent cliff, which is projected to fuel the biosimilar business. As a result, the number of research and development (R&D) efforts done by enterprises to commercialize the generic molecule is projected to rise. The need for cro service providers will be fueled by the race to launch the molecule on a reasonable timetable and budget.

• Preclinical studies

Tier 1 pharma and biotechnology businesses most frequently outsource toxicology and pharmacokinetic investigations in preclinical studies. The time and cost effectiveness given by the providers of such services have been highlighted as the main motivations for outsourcing activities. These activities are likely to increase throughout the projection period as pharmaceutical companies increase their attention and R&D budget allocation for the creation of new products.

• Rise in number of therapies

 The number of late-stage pipeline therapies increased by 19 percent to 849 (2018) from 711 (2017), owing to the increasing number of precision therapies in the oncology pipeline and the large number of pipeline medications. The use of oncology-based in-vivo cro aids in the development of new treatments for cancer prevention, analysis, and treatment, which is expected to drive the global market forward.

Opportunities

An increase in the geriatric population has also supported the expansion of the oncology-based in vivo contract research organization (CRO) market. Due to the increasing number of specific therapies in the oncology pipeline and the presence of a large number of pipeline drugs, as well as the use of oncology-based in-vivo cro to aid in the development of novel therapies for the diagnosis, prevention, and treatment of patients, the number of late-stage pipeline therapies increased from 711 in 2017 to 849 in 2018, a 19% increase, which is expected to further boost market growth.

Restraints/Challenges

However, some constraints affecting the in vivo contract research organization (CRO) market revenue growth include pharmaceutical companies' shifting preference for outsourcing clinical and preclinical trials in order to focus on their core business, high clinical trial costs, and CRO quality issues. Furthermore, other issues, such as the availability of suitable animals for certain testing, are hampering the in vivo contract research organization (CRO) market revenue growth.

This in vivo contract research organization (CRO) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the In vivo CRO market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on In Vivo Contract Research Organization (CRO) Market

While planning, developing, and caring for others and their families during COVID-19, health professionals are nervous, overworked, and financially insecure. We must help them accomplish their duties, stay safe, and stay alive. Future research should look on health professionals' worries and coping methods during pandemics. The market suffered a setback as a result of the introduction of tight lockdown measures and travel restrictions during COVID-19. However, this pandemic has brought to light an even larger need for a paradigm shift in cancer research.

Global In Vivo Contract Research Organization (CRO) Market Scope

The in vivo contract research organization (CRO) market is segmented on the basis of product, applications and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product type

•  Rodent Based
•  Non Rodent Based

Applications 

• Autoimmune
•  Pain Management
•  Oncology
•  CNS Conditions
•  Diabetes
•  Obesity
•  Others

In Vivo Contract Research Organization (CRO) Market Regional Analysis/Insights

The in vivo contract research organization (CRO) market is analysed and market size insights and trends are provided by country, product, applications and end-user as referenced above.

The countries covered in the in vivo contract research organization (CRO) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominated other regional markets in terms of revenue share in 2020 with major contribution from the U.S. Furthermore, the region's scientific activities have been strengthened by increased funding. Increasing healthcare spending and the availability of money and grants from government agencies such as the National Institutes of Health (NIH) to support research operations are all contributing to the regional market's revenue growth.

Asia Pacific is the fastest growing market owing to many advanced countries investing in this region and various alterations made by the regulatory market to change the clinical trials assessment standards to match the global platform.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The in vivo contract research organization (CRO) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for in vivo CRO market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the in vivo contract research organization (CRO) market. The data is available for historic period 2010-2020.

Competitive Landscape and In Vivo Contract Research Organization (CRO) Market Share Analysis

The in vivo contract research organization (CRO) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to in vivo contract research organization (CRO) market.

Some of the major players operating in the in vivo contract research organization (CRO) Market are:

• PPD Inc. (U.S)
• Quintiles (U.S)
• ICON Plc (Ireland)
• Parexel International Corporation (U.S)
• American Preclinical Services, LLC (U.S)
• Labcorp Drug Development (U.S)
• Theorem Clinical research (U.S)
• WuXi AppTec (China)
• Syneos Health (U.S)
• Evotec (Germany)
• Charles River Laboratories (U.S)

SKU-68336